$PAVM
PAVmed Inc. Stock $pavm

$pavm Overview Financials Valuation SEC Filings Company Website

2023 Q3 Form 10-Q Financial Statement

#000149315223028578 Filed on August 14, 2023

Income Statement

Concept	2023 Q3	2023 Q2	2022 Q2
Revenue	$791.0K	$166.0K
YoY Change	940.79%
Cost Of Revenue	$1.779M	$1.685M
YoY Change	9.41%
Gross Profit	-$988.0K	-$1.519M
YoY Change	-36.26%
Gross Profit Margin	-124.91%	-915.06%
Selling, General & Admin	$10.87M	$10.99M	$16.74M
YoY Change	-27.78%	-34.33%	92.11%
% of Gross Profit
Research & Development	$3.161M	$3.469M	$6.740M
YoY Change	-49.03%	-48.53%	58.29%
% of Gross Profit
Depreciation & Amortization	$740.0K	$747.0K	$938.0K
YoY Change	5.71%	-20.36%	5111.11%
% of Gross Profit
Operating Expenses	$14.04M	$14.46M	$23.48M
YoY Change	-33.98%	-38.41%	81.01%
Operating Profit	-$15.53M	-$16.48M	-$23.48M
YoY Change	-33.39%	-29.79%	81.01%
Interest Expense	-$4.460M	-$665.0K	-$523.0K
YoY Change	1589.39%	27.15%
% of Operating Profit
Other Income/Expense, Net	-$6.222M	-$1.408M	-$5.624M
YoY Change	-6.0%	-74.96%	-1974.67%
Pretax Income	-$21.75M	-$17.89M	-$29.10M
YoY Change	-27.34%	-38.52%	129.68%
Income Tax
% Of Pretax Income
Net Earnings	-$17.67M	-$14.54M	-$25.53M
YoY Change	-32.36%	-43.05%	122.52%
Net Earnings / Revenue	-2234.01%	-8757.23%
Basic Earnings Per Share	-$0.16	-$0.14	-$0.29
Diluted Earnings Per Share	-$0.16	-$0.14	-$293.5K
COMMON SHARES
Basic Shares Outstanding	111.4M shares	104.5M shares	86.96M shares
Diluted Shares Outstanding	111.9M shares	104.3M shares	86.96M shares

Balance Sheet

Concept	2023 Q3	2023 Q2	2022 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$30.99M	$41.48M	$68.47M
YoY Change	-49.0%	-39.42%	58.46%
Cash & Equivalents	$26.41M	$37.16M	$65.15M
Short-Term Investments
Other Short-Term Assets	$1.440M	$1.609M	$2.345M
YoY Change	21.72%	-31.39%	-24.98%
Inventory
Prepaid Expenses
Receivables	$36.00K	$41.00K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$32.46M	$43.13M	$70.82M
YoY Change	-47.63%	-39.1%	52.83%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.820M	$2.028M	$2.253M
YoY Change	-23.34%	-9.99%
Goodwill
YoY Change
Intangibles	$1.929M	$2.435M	$4.456M
YoY Change	-51.16%	-45.35%
Long-Term Investments
YoY Change
Other Assets	$1.147M	$1.079M	$1.725M
YoY Change	5.91%	-37.45%	66.67%
Total Long-Term Assets	$9.559M	$10.56M	$11.64M
YoY Change	-8.84%	-9.3%	1024.54%
TOTAL ASSETS
Total Short-Term Assets	$32.46M	$43.13M	$70.82M
Total Long-Term Assets	$9.559M	$10.56M	$11.64M
Total Assets	$42.02M	$53.68M	$82.45M
YoY Change	-42.01%	-34.89%	74.06%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.165M	$1.162M	$4.492M
YoY Change	-11.78%	-74.13%	19.28%
Accrued Expenses	$5.485M	$4.946M	$2.932M
YoY Change	87.2%	68.69%	87.35%
Deferred Revenue
YoY Change
Short-Term Debt	$46.56M	$44.42M	$30.44M
YoY Change	27.47%	45.9%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$54.51M	$50.79M	$38.87M
YoY Change	30.05%	30.66%	629.08%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$3.340M	$3.728M	$2.183M
YoY Change	67.17%	70.77%
Total Long-Term Liabilities	$3.340M	$3.728M	$2.183M
YoY Change	67.17%	70.77%
TOTAL LIABILITIES
Total Short-Term Liabilities	$54.51M	$50.79M	$38.87M
Total Long-Term Liabilities	$3.340M	$3.728M	$2.183M
Total Liabilities	$57.85M	$54.51M	$41.05M
YoY Change	31.75%	32.8%	828.73%
SHAREHOLDERS EQUITY
Retained Earnings	-$278.5M	-$260.8M	-$181.4M
YoY Change	34.14%	43.73%
Common Stock	$120.0K	$109.0K	$87.00K
YoY Change	30.43%	25.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)			$548.0K
YoY Change
Treasury Stock Shares
Shareholders Equity	-$43.26M	-$31.51M	$21.98M
YoY Change
Total Liabilities & Shareholders Equity	$42.02M	$53.68M	$82.45M
YoY Change	-42.01%	-34.89%	74.06%

Cashflow Statement

Concept	2023 Q3	2023 Q2	2022 Q2
OPERATING ACTIVITIES
Net Income	-$17.67M	-$14.54M	-$25.53M
YoY Change	-32.36%	-43.05%	122.52%
Depreciation, Depletion And Amortization	$740.0K	$747.0K	$938.0K
YoY Change	5.71%	-20.36%	5111.11%
Cash From Operating Activities	-$11.09M	-$12.79M	-$22.56M
YoY Change	-42.66%	-43.32%	240.45%
INVESTING ACTIVITIES
Capital Expenditures	$20.00K	$15.00K	-$352.0K
YoY Change	-106.33%	-104.26%	200.85%
Acquisitions
YoY Change
Other Investing Activities	$0.00	$0.00	-$2.200M
YoY Change	-100.0%	-100.0%	4580.85%
Cash From Investing Activities	-$20.00K	-$15.00K	-$2.552M
YoY Change	-98.48%	-99.41%	1456.1%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	360.0K	684.0K	25.53M
YoY Change	-97.07%	-97.32%	1643.58%
NET CHANGE
Cash From Operating Activities	-11.09M	-12.79M	-22.56M
Cash From Investing Activities	-20.00K	-15.00K	-2.552M
Cash From Financing Activities	360.0K	684.0K	25.53M
Net Change In Cash	-10.75M	-12.12M	416.0K
YoY Change	28.47%	-3012.74%	-107.81%
FREE CASH FLOW
Cash From Operating Activities	-$11.09M	-$12.79M	-$22.56M
Capital Expenditures	$20.00K	$15.00K	-$352.0K
Free Cash Flow	-$11.11M	-$12.80M	-$22.21M
YoY Change	-41.6%	-42.35%	241.16%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures		usd
	dei	Entity Central Index Key EntityCentralIndexKey	0001624326
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent		usd
CY2023Q2	us-gaap	Treasury Stock Value TreasuryStockValue		usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax		usd
CY2022Q2	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost		usd
	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost		usd
CY2022Q2	PAVM	Change In Fair Value Derivative Liability ChangeInFairValueDerivativeLiability		usd
	PAVM	Change In Fair Value Derivative Liability ChangeInFairValueDerivativeLiability		usd
CY2022Q2	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets		usd
CY2023Q2	PAVM	Dividends Series B Convertible Preferred Stock DividendsSeriesBConvertiblePreferredStock		usd
CY2023Q2	PAVM	Stock Issued During The Periof Of New Issue Impact Of Subsidiary Equity Transactions StockIssuedDuringThePeriofOfNewIssueImpactOfSubsidiaryEquityTransactions		usd
	PAVM	Dividends Series B Convertible Preferred Stock DividendsSeriesBConvertiblePreferredStock		usd
	PAVM	Stock Issued During The Periof Of New Issue Impact Of Subsidiary Equity Transactions StockIssuedDuringThePeriofOfNewIssueImpactOfSubsidiaryEquityTransactions		usd
	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued		usd
CY2022Q2	PAVM	Dividends Series B Convertible Preferred Stock DividendsSeriesBConvertiblePreferredStock		usd
	PAVM	Dividends Series B Convertible Preferred Stock DividendsSeriesBConvertiblePreferredStock		usd
	PAVM	Issue Common Stock Exercise Series Z Warrants Value IssueCommonStockExerciseSeriesZWarrantsValue		usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets		usd
	PAVM	Issue Common Stock Vendor Service Agreement IssueCommonStockVendorServiceAgreement		usd
	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost		usd
	PAVM	Change In Fair Value Derivative Liability ChangeInFairValueDerivativeLiability		usd
	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale		usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired		usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering		usd
	PAVM	Proceeds From Issuance Of Common Stock At The Market Facility ProceedsFromIssuanceOfCommonStockAtTheMarketFacility		usd
	PAVM	Proceeds Majorityowned Subsidiary Common Stock Atthemarket Facility ProceedsMajorityownedSubsidiaryCommonStockAtthemarketFacility		usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised		usd
	PAVM	Proceeds Majorityowned Subsidiary Common Stock Employee Stock Purchase Plan ProceedsMajorityownedSubsidiaryCommonStockEmployeeStockPurchasePlan		usd
	PAVM	Proceeds From Exercise Of Stock Options Issued Under Equity Plan Of Majority Owned Subsidiary ProceedsFromExerciseOfStockOptionsIssuedUnderEquityPlanOfMajorityOwnedSubsidiary		usd
	PAVM	Purchase Treasury Stock Payment Of Employee Payroll Tax Obligation In Connection With Stockbased Compensation PurchaseTreasuryStockPaymentOfEmployeePayrollTaxObligationInConnectionWithStockbasedCompensation		usd
	dei	Document Type DocumentType	10-Q
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2023-06-30
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	001-37685
	dei	Entity Registrant Name EntityRegistrantName	PAVMED INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	47-1214177
	dei	Entity Address Address Line1 EntityAddressAddressLine1	360 Madison Avenue
	dei	Entity Address Address Line2 EntityAddressAddressLine2	25th Floor
	dei	Entity Address City Or Town EntityAddressCityOrTown	New York
	dei	Entity Address State Or Province EntityAddressStateOrProvince	NY
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	10017
	dei	City Area Code CityAreaCode	(212)
	dei	Local Phone Number LocalPhoneNumber	949-4319
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	true
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2023Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	111418679	shares
CY2023Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37163000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	39744000	usd
CY2023Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	41000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	17000	usd
CY2023Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	5923000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	4165000	usd
CY2023Q2	us-gaap	Assets Current AssetsCurrent	43127000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	43926000	usd
CY2023Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2028000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	2451000	usd
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5014000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3037000	usd
CY2023Q2	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	2435000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	3445000	usd
CY2023Q2	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1079000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1121000	usd
CY2023Q2	us-gaap	Assets Assets	53683000	usd
CY2022Q4	us-gaap	Assets Assets	53980000	usd
CY2023Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	1162000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2704000	usd
CY2023Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	4946000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3705000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1427000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1141000	usd
CY2023Q2	us-gaap	Secured Debt Current SecuredDebtCurrent	42990000	usd
CY2022Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	33650000	usd
CY2023Q2	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	260000	usd
CY2023Q2	us-gaap	Liabilities Current LiabilitiesCurrent	50785000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	41200000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3728000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1846000	usd
CY2023Q2	us-gaap	Liabilities Liabilities	54513000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	43046000	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	20000000	shares
CY2023Q2	us-gaap	Preferred Stock Value PreferredStockValue	2841000	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	2695000	usd
CY2023Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2023Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	250000000	shares
CY2023Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	108537994	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	94510537	shares
CY2023Q2	us-gaap	Common Stock Value CommonStockValue	109000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	95000	usd
CY2023Q2	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	226321000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	216106000	usd
CY2023Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-260783000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-228169000	usd
CY2022Q4	us-gaap	Treasury Stock Value TreasuryStockValue	408000	usd
CY2023Q2	us-gaap	Stockholders Equity StockholdersEquity	-31512000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-9681000	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	30682000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	20615000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-830000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10934000	usd
CY2023Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53683000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	53980000	usd
CY2023Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	166000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	612000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	189000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	1685000	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
	us-gaap	Cost Of Revenue CostOfRevenue	3030000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	369000	usd
CY2023Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4339000	usd
CY2022Q2	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4898000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8877000	usd
	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	8823000	usd
CY2023Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	6652000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	11196000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	16670000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	20672000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	505000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	650000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1010000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	773000	usd
CY2023Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3469000	usd
CY2022Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6740000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7909000	usd
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12671000	usd
CY2023Q2	us-gaap	Costs And Expenses CostsAndExpenses	16650000	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	23484000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	37496000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	43308000	usd
CY2023Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-16484000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-23484000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-36884000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-43119000	usd
CY2023Q2	us-gaap	Interest Income Operating InterestIncomeOperating	163000	usd
CY2022Q2	us-gaap	Interest Income Operating InterestIncomeOperating	7000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	283000	usd
	us-gaap	Interest Income Operating InterestIncomeOperating	9000	usd
CY2023Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	228000	usd
CY2022Q2	us-gaap	Interest Expense Debt InterestExpenseDebt	523000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	411000	usd
	us-gaap	Interest Expense Debt InterestExpenseDebt	523000	usd
CY2023Q2	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	340000	usd
CY2022Q2	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	2000000	usd
	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	1380000	usd
	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	2000000	usd
CY2022Q2	PAVM	Loss On Issue And Offering Cost Senior Secured Convertible Note LossOnIssueAndOfferingCostSeniorSecuredConvertibleNote	3101000	usd
	PAVM	Loss On Issue And Offering Cost Senior Secured Convertible Note LossOnIssueAndOfferingCostSeniorSecuredConvertibleNote	1186000	usd
	PAVM	Loss On Issue And Offering Cost Senior Secured Convertible Note LossOnIssueAndOfferingCostSeniorSecuredConvertibleNote	3101000	usd
CY2023Q2	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-743000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-1268000	usd
CY2023Q2	PAVM	Change In Fair Value Derivative Liability ChangeInFairValueDerivativeLiability	260000	usd
	PAVM	Change In Fair Value Derivative Liability ChangeInFairValueDerivativeLiability	260000	usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	1000000	usd
CY2023Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-1408000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5617000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-3222000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-5615000	usd
CY2023Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17892000	usd
CY2022Q2	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-29101000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-40106000	usd
	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-48734000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-17892000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-29101000	usd
	us-gaap	Profit Loss ProfitLoss	-40106000	usd
	us-gaap	Profit Loss ProfitLoss	-48734000	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3355000	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3576000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-7638000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6337000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-14537000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-25525000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-32468000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-42397000	usd
CY2023Q2	PAVM	Series B Preferred Stock Dividends Income Statement Impact SeriesBPreferredStockDividendsIncomeStatementImpact	75000	usd
CY2022Q2	PAVM	Series B Preferred Stock Dividends Income Statement Impact SeriesBPreferredStockDividendsIncomeStatementImpact	70000	usd
	PAVM	Series B Preferred Stock Dividends Income Statement Impact SeriesBPreferredStockDividendsIncomeStatementImpact	149000	usd
	PAVM	Series B Preferred Stock Dividends Income Statement Impact SeriesBPreferredStockDividendsIncomeStatementImpact	138000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14612000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25595000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32617000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-42535000	usd
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
CY2023Q2	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic NetLossAttributableToCommonStockholdersPerShareBasic	-0.14
CY2023Q2	PAVM	Net Loss Attributable To Common Stockholders Per Share Diluted NetLossAttributableToCommonStockholdersPerShareDiluted	-0.14
CY2022Q2	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic NetLossAttributableToCommonStockholdersPerShareBasic	-0.29
CY2022Q2	PAVM	Net Loss Attributable To Common Stockholders Per Share Diluted NetLossAttributableToCommonStockholdersPerShareDiluted	-0.29
	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic NetLossAttributableToCommonStockholdersPerShareBasic	-0.32
	PAVM	Net Loss Attributable To Common Stockholders Per Share Diluted NetLossAttributableToCommonStockholdersPerShareDiluted	-0.32
	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic NetLossAttributableToCommonStockholdersPerShareBasic	-0.49
	PAVM	Net Loss Attributable To Common Stockholders Per Share Diluted NetLossAttributableToCommonStockholdersPerShareDiluted	-0.49
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104349822	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	104349822	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86957352	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	86957352	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100742530	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100742530	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86689857	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	86689857	shares
CY2023Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10804000	usd
CY2023Q2	PAVM	Stock Issued During Period Value Atm Facility StockIssuedDuringPeriodValueATMFacility	609000	usd
CY2023Q2	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	2393000	usd
CY2023Q2	PAVM	Issuance Vendor Service Agreement IssuanceVendorServiceAgreement	749000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	1090000	usd
CY2023Q2	PAVM	Stockbased Compensation Majorityowned Subsidiary StockbasedCompensationMajorityownedSubsidiary	1417000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-17892000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-830000	usd
CY2022Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	10934000	usd
	PAVM	Stock Issued During Period Value Atm Facility StockIssuedDuringPeriodValueATMFacility	1166000	usd
	PAVM	Issue Common Stock Upon Partial Conversions Of Senior Secured Convertible Note IssueCommonStockUponPartialConversionsOfSeniorSecuredConvertibleNote	4421000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	182000	usd
	us-gaap	Noncontrolling Interest Increase From Subsidiary Equity Issuance NoncontrollingInterestIncreaseFromSubsidiaryEquityIssuance	276000	usd
	PAVM	Issuance Majorityowned Subsidiary Common Stock Committed Equity Facility Net Of Deferred Financing Charges IssuanceMajorityownedSubsidiaryCommonStockCommittedEquityFacilityNetOfDeferredFinancingCharges	284000	usd
	PAVM	Issuance Majorityowned Subsidiary Common Stock Settlement Apardx Installment Payment IssuanceMajorityownedSubsidiaryCommonStockSettlementApardxInstallmentPayment	713000	usd
	PAVM	Issuance Vendor Service Agreement IssuanceVendorServiceAgreement	749000	usd
	PAVM	Issuance Majorityowned Subsidiary Preferred Stock IssuanceMajorityownedSubsidiaryPreferredStock	13625000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	2288000	usd
	PAVM	Stockbased Compensation Majorityowned Subsidiary StockbasedCompensationMajorityownedSubsidiary	4638000	usd
	us-gaap	Profit Loss ProfitLoss	-40106000	usd
CY2023Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	-830000	usd
CY2022Q1	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	64733000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-1000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	61000	usd
CY2022Q2	PAVM	Adjustment To Additional Paid In Capital Issue Common Stock Of Majorityowned Subsidiary AdjustmentToAdditionalPaidInCapitalIssueCommonStockOfMajorityownedSubsidiary	501000	usd
CY2022Q2	PAVM	Stock Issued During The Periof Of New Issue Impact Of Subsidiary Equity Transactions StockIssuedDuringThePeriofOfNewIssueImpactOfSubsidiaryEquityTransactions	241000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	1449000	usd
CY2022Q2	PAVM	Stockbased Compensation Majorityowned Subsidiary StockbasedCompensationMajorityownedSubsidiary	3557000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	-36000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-29101000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41404000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	79418000	usd
CY2021Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	79418000	usd
	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	-1000	usd
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	303000	usd
	PAVM	Adjustment To Additional Paid In Capital Issue Common Stock Of Majorityowned Subsidiary AdjustmentToAdditionalPaidInCapitalIssueCommonStockOfMajorityownedSubsidiary	688000	usd
	us-gaap	Stock Issued During Period Value Employee Stock Purchase Plan StockIssuedDuringPeriodValueEmployeeStockPurchasePlan	217000	usd
	PAVM	Stock Issued During The Periof Of New Issue Impact Of Subsidiary Equity Transactions StockIssuedDuringThePeriofOfNewIssueImpactOfSubsidiaryEquityTransactions	241000	usd
	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Employee Stock Purchase Program Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationEmployeeStockPurchaseProgramRequisiteServicePeriodRecognition	2726000	usd
	PAVM	Stockbased Compensation Majorityowned Subsidiary StockbasedCompensationMajorityownedSubsidiary	7094000	usd
	us-gaap	Stock Issued During Period Value Treasury Stock Reissued StockIssuedDuringPeriodValueTreasuryStockReissued	-548000	usd
	us-gaap	Profit Loss ProfitLoss	-48734000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41404000	usd
CY2022Q2	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	41404000	usd
	us-gaap	Profit Loss ProfitLoss	-40106000	usd
	us-gaap	Profit Loss ProfitLoss	-48734000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1474000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	1031000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6926000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9820000	usd
	us-gaap	Gain Loss On Disposition Of Intangible Assets GainLossOnDispositionOfIntangibleAssets	1000000	usd
	PAVM	Issuance Of Common Stock Installment Settlement Payment IssuanceOfCommonStockInstallmentSettlementPayment	713000	usd
	PAVM	Issuance Of Common Stock Installment Settlement Payment IssuanceOfCommonStockInstallmentSettlementPayment	239000	usd
	PAVM	Issue Common Stock Vendor Service Agreement IssueCommonStockVendorServiceAgreement	625000	usd
	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	1380000	usd
	PAVM	Change In Fair Value Senior Secured Convertible Note ChangeInFairValueSeniorSecuredConvertibleNote	2000000	usd
	PAVM	Loss On Issue And Offering Costs Senior Secured Convertible Note LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote	1111000	usd
	PAVM	Loss On Issue And Offering Costs Senior Secured Convertible Note LossOnIssueAndOfferingCostsSeniorSecuredConvertibleNote	2500000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt Before Write Off Of Deferred Debt Issuance Cost GainsLossesOnExtinguishmentOfDebtBeforeWriteOffOfDeferredDebtIssuanceCost	-1268000	usd
	PAVM	Change In Fair Value Derivative Liability ChangeInFairValueDerivativeLiability	260000	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	192000	usd
	us-gaap	Other Noncash Expense OtherNoncashExpense	57000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	24000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-200000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	1592000	usd
	us-gaap	Increase Decrease In Prepaid Expenses Other IncreaseDecreaseInPrepaidExpensesOther	1665000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	-1541000	usd
	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1057000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	1241000	usd
	us-gaap	Increase Decrease In Accrued Liabilities And Other Operating Liabilities IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities	-1326000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-29073000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-34821000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	41000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	926000	usd
	us-gaap	Proceeds From Sale Of Property Held For Sale ProceedsFromSaleOfPropertyHeldForSale	1000000	usd
	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	2200000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	959000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-3126000	usd
	us-gaap	Proceeds From Issuance Initial Public Offering ProceedsFromIssuanceInitialPublicOffering	13625000	usd
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	10000000	usd
	us-gaap	Proceeds From Issuance Of Secured Debt ProceedsFromIssuanceOfSecuredDebt	25000000	usd
	PAVM	Proceeds From Issuance Of Common Stock At The Market Facility ProceedsFromIssuanceOfCommonStockAtTheMarketFacility	1166000	usd
	PAVM	Proceeds Majorityowned Subsidiary Common Stock Atthemarket Facility ProceedsMajorityownedSubsidiaryCommonStockAtthemarketFacility	284000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	303000	usd
	PAVM	Proceeds From Issue Of Common Stock Employee Stock Purchase Plan ProceedsFromIssueOfCommonStockEmployeeStockPurchasePlan	182000	usd
	PAVM	Proceeds From Issue Of Common Stock Employee Stock Purchase Plan ProceedsFromIssueOfCommonStockEmployeeStockPurchasePlan	217000	usd
	PAVM	Proceeds Majorityowned Subsidiary Common Stock Employee Stock Purchase Plan ProceedsMajorityownedSubsidiaryCommonStockEmployeeStockPurchasePlan	276000	usd
	PAVM	Proceeds From Exercise Of Stock Options Issued Under Equity Plan Of Majority Owned Subsidiary ProceedsFromExerciseOfStockOptionsIssuedUnderEquityPlanOfMajorityOwnedSubsidiary	688000	usd
	PAVM	Purchase Treasury Stock Payment Of Employee Payroll Tax Obligation In Connection With Stockbased Compensation PurchaseTreasuryStockPaymentOfEmployeePayrollTaxObligationInConnectionWithStockbasedCompensation	366000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25533000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	25842000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-2581000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-12105000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	39744000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	77258000	usd
CY2023Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	37163000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	65153000	usd
	us-gaap	Nature Of Operations NatureOfOperations	<p id="xdx_805_eus-gaap--NatureOfOperations_zYzhlhfn1AJl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Note 1 — <span id="xdx_828_zHsmTlEsV5ml">The Company</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><i>Description of the Business</i></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">PAVmed Inc. and Subsidiaries, referred to herein as “PAVmed” or the “Company,” is comprised of PAVmed Inc. and its wholly-owned subsidiary and its majority-owned subsidiaries, inclusive of Lucid Diagnostics Inc. (“Lucid Diagnostics” or “Lucid”) and Veris Health Inc. (“Veris Health” or “Veris”).</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">PAVmed is a diversified commercial-stage medical technology company operating in the medical device, diagnostics, and digital health sectors, including through Lucid Diagnostics, a commercial-stage cancer prevention diagnostics company, and Veris Health, a private digital health company focused on enhanced personalized cancer care through remote patient monitoring using implantable biologic sensors with wireless communication along with a custom suite of connected external devices. The Company’s current central focus is on the commercialization of Lucid’s EsoGuard assay and Veris Health’s Veris Cancer Care Platform. As resources permit, we will continue to explore internal and external innovations that fulfill our project selection criteria without limiting ourselves to any target specialty or condition.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><i> </i></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">The Company has financed its operations principally through public and private issuances of its common stock, preferred stock, common stock purchase warrants, and debt. The Company is subject to all of the risks and uncertainties typically faced by medical device and diagnostic companies that devote substantially all of their efforts to the commercialization of their initial product and services and ongoing research and development activities and conducting clinical trials. The Company expects to continue to experience recurring losses from operations and will continue to fund its operations with debt and equity financing transactions. Notwithstanding, however, with the cash on-hand as of the date hereof and other debt and equity committed sources of financing, the Company expects to be able to fund its operations for one year from the date of the issue of the Company’s consolidated financial statements included herein in the Company’s Quarterly Report on Form 10-Q for the period ended June 30, 2023.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_845_eus-gaap--UseOfEstimates_z0mptfxJPy54" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_86D_zKClkOZNaggi">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">In preparing the unaudited condensed consolidated financial statements in conformity with U.S. GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and the determination of corresponding carrying value reserve, if any, and liabilities and the disclosure of contingent losses, as of the date of the consolidated financial statements, as well as the reported amounts of revenue and expenses during the reporting period. Significant estimates in these unaudited condensed consolidated financial statements include those related to the estimated fair value of debt obligations, stock-based equity awards, intangible assets and common stock purchase warrants. Other significant estimates include the estimated incremental borrowing rate, the provision or benefit for income taxes and the corresponding valuation allowance on deferred tax assets. Additionally, management’s assessment of the Company’s ability to continue as a going concern involves the estimation of the amount and timing of future cash inflows and outflows. On an ongoing basis, the Company evaluates its estimates and assumptions. The Company bases its estimates on historical experience and on various other assumptions believed to be reasonable. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p>
	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_846_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zpkqBI2CR3lj" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b><span id="xdx_865_zv0579zaVQ7b">Reclassifications</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.25in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black">Certain prior-year amounts have been reclassified to conform to the current year presentation, which includes presenting costs of revenue within operating expenses on the statements of operations, in the unaudited condensed consolidated financial statements and accompanying notes to the unaudited condensed consolidated financial statements. The impact of the reclassifications made to prior year amounts is not material and did not affect net loss.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 9pt"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b>Note 2 — Summary of Significant Accounting Policies</b> - continued</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; color: Black"><b> </b></span></p>
CY2023Q2	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	166000	usd
	us-gaap	Revenue From Contract With Customer Including Assessed Tax RevenueFromContractWithCustomerIncludingAssessedTax	612000	usd
	PAVM	Monthly Fees MonthlyFees	100000	usd
CY2023Q2	us-gaap	Cost Of Revenue CostOfRevenue	1685000	usd
	us-gaap	Cost Of Revenue CostOfRevenue	3030000	usd
CY2022Q2	us-gaap	Cost Of Revenue CostOfRevenue	0	usd
	us-gaap	Cost Of Revenue CostOfRevenue	369000	usd
CY2023Q2	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	71000	usd
CY2022Q2	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	543000	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	718000	usd
	us-gaap	Costs And Expenses Related Party CostsAndExpensesRelatedParty	882000	usd
CY2022Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	650000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	1010000	usd
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	773000	usd
CY2023Q2	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	42000	usd
CY2023Q2	PAVM	Debt Instruments Fair Value DebtInstrumentsFairValue	340000	usd
CY2023Q2	PAVM	Prepaid Service Providers And Suppliers PrepaidServiceProvidersAndSuppliers	567000	usd
CY2022Q4	PAVM	Prepaid Service Providers And Suppliers PrepaidServiceProvidersAndSuppliers	599000	usd
CY2023Q2	us-gaap	Prepaid Insurance PrepaidInsurance	799000	usd
CY2022Q4	us-gaap	Prepaid Insurance PrepaidInsurance	300000	usd
CY2023Q2	us-gaap	Security Deposit SecurityDeposit	4314000	usd
CY2022Q4	us-gaap	Security Deposit SecurityDeposit	3005000	usd
CY2023Q2	PAVM	Esocheck Cell Collection Prepaid Supplies EsocheckCellCollectionPrepaidSupplies	39000	usd
CY2022Q4	PAVM	Esocheck Cell Collection Prepaid Supplies EsocheckCellCollectionPrepaidSupplies	59000	usd
CY2023Q2	PAVM	Esoguard Mailer Prepaid Supplies EsoguardMailerPrepaidSupplies	3000	usd
CY2022Q4	PAVM	Esoguard Mailer Prepaid Supplies EsoguardMailerPrepaidSupplies	52000	usd
CY2023Q2	PAVM	Veris Box Supplies VerisBoxSupplies	201000	usd
CY2022Q4	PAVM	Veris Box Supplies VerisBoxSupplies	150000	usd
CY2023Q2	PAVM	Prepaid Expense Deposits And Other Assets Current PrepaidExpenseDepositsAndOtherAssetsCurrent	5923000	usd
CY2022Q4	PAVM	Prepaid Expense Deposits And Other Assets Current PrepaidExpenseDepositsAndOtherAssetsCurrent	4165000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	844000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	1825000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	835000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	787000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	617000	usd
CY2023Q2	PAVM	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	1319000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	6227000	usd
CY2023Q2	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	1072000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	5155000	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	44300000	usd
CY2023Q1	PAVM	Other Income Expense Change In Fair Value OtherIncomeExpenseChangeInFairValue	1040000	usd
CY2023Q2	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	1608000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	705000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	483000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	2689000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	3633000	usd
CY2023Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y9M
CY2022Q2	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P3Y3M21D
CY2023Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07875	pure
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.07875	pure
CY2023Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5014000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	3037000	usd
CY2023Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	5155000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	2987000	usd
CY2023Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1427000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1141000	usd
CY2023Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3728000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	1846000	usd
CY2022Q3	us-gaap	Payments For Rent PaymentsForRent	3200000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5375000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Gross FiniteLivedIntangibleAssetsGross	5375000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	2940000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	1930000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2435000	usd
CY2022Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	3445000	usd
CY2023Q2	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	505000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Remainder Of Fiscal Year FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear	1011000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	688000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	421000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	315000	usd
CY2023Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	2435000	usd
CY2023Q2	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	43250000	usd
CY2022Q4	us-gaap	Financial Liabilities Fair Value Disclosure FinancialLiabilitiesFairValueDisclosure	33650000	usd
CY2023Q2	PAVM	Fair Value Measurements Description FairValueMeasurementsDescription	is equal-to or greater than $750, then no further contractual consideration is required. However, if such fair market value is less than $750, then, the Company will incur an additional contractual consideration obligation in amount equal to the difference between the required minimum fair market value of $750 and the contractual formula based computed fair market value
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	262000	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	260000	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	262000	usd
CY2023Q2	us-gaap	Derivative Liabilities DerivativeLiabilities	260000	usd
CY2023Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	40915000	usd
CY2023Q2	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	42990000	usd
CY2022Q4	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	32747000	usd
CY2022Q4	us-gaap	Debt Instrument Fair Value DebtInstrumentFairValue	33650000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	33650000	usd
CY2023Q1	us-gaap	Debt Instrument Issued Principal DebtInstrumentIssuedPrincipal	11111000	usd
CY2023Q1	PAVM	Fair Value Adjustment Issue Date FairValueAdjustmentIssueDate	789000	usd
CY2023Q1	us-gaap	Debt Instrument Periodic Payment DebtInstrumentPeriodicPayment	1335000	usd
CY2023Q1	us-gaap	Debt Instrument Repaid Principal DebtInstrumentRepaidPrincipal	166000	usd
CY2023Q1	PAVM	Debt Instruments Fair Value DebtInstrumentsFairValue	251000	usd
CY2023Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	44300000	usd
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	42990000	usd
CY2023Q2	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	42990000	usd
CY2023Q2	PAVM	Other Income Expense Change In Fair Value OtherIncomeExpenseChangeInFairValue	340000	usd
	PAVM	Other Income Expense Change In Fair Value OtherIncomeExpenseChangeInFairValue	1380000	usd
CY2023Q2	us-gaap	Share Based Compensation ShareBasedCompensation	2507000	usd
CY2022Q2	us-gaap	Share Based Compensation ShareBasedCompensation	5007000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	6926000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	9820000	usd
CY2022Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	the Company received a notice from the Listing Qualifications Department of Nasdaq stating that, for the prior 30 consecutive business days (through December 28, 2022), the closing bid price of the Company’s common stock had been below the minimum of $1 per share required for continued listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2). The notification letter stated that the Company would be afforded 180 calendar days (until June 27, 2023) to regain compliance. On June 28, 2023, the Company received a second notice from the Listing Qualifications Department of Nasdaq granting the Company a 180-day extension (or until December 26, 2023) to regain compliance with the minimum bid price requirement. In order to regain compliance, the closing bid price of the Company’s common stock must be at least $1 for a minimum of ten consecutive business days
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	the Company’s Certificate of Incorporation, to effect, at any time prior to the one-year anniversary date of the Special Meeting, (i) a reverse split of the Company’s outstanding shares of common stock at a specific ratio, ranging from 1-for-5 to 1-for-15, to be determined by the board of directors of the Company in its sole discretion, and (ii) an associated reduction in the number of shares of common stock the Company is authorized to issue, from 250,000,000 shares to 50,000,000 shares. If the Company’s board of directors authorizes the Company to consummate the reverse stock split, the Company anticipates it will regain compliance with the Nasdaq requirements for continued listing through such transaction
	PAVM	Stock Issued During Period Share Atm Facilities StockIssuedDuringPeriodShareATMFacilities	2330747	shares
	PAVM	Stock Issued During Period Value Atm Facilities StockIssuedDuringPeriodValueATMFacilities	1165000	usd
CY2022Q4	us-gaap	Minority Interest MinorityInterest	20615000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-7638000	usd
	PAVM	Impact Of Subsidiary Equity Transactions ImpactOfSubsidiaryEquityTransactions	-1332000	usd
	PAVM	Issuance Majorityowned Subsidiary Preferred Stock IssuanceMajorityownedSubsidiaryPreferredStock	13625000	usd
	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value One AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueOne	284000	usd
	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value Two AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueTwo	713000	usd
	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value Three AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueThree	147000	usd
	PAVM	Adjustments To Additional Paid In Capital Minority Interest Requisite Service Period Recognition Value Four AdjustmentsToAdditionalPaidInCapitalMinorityInterestRequisiteServicePeriodRecognitionValueFour	276000	usd
	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	3982000	usd
	PAVM	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Values AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValues	10000	usd
CY2023Q2	us-gaap	Minority Interest MinorityInterest	30682000	usd
CY2023Q2	us-gaap	Profit Loss ProfitLoss	-17892000	usd
CY2022Q2	us-gaap	Profit Loss ProfitLoss	-29101000	usd
	us-gaap	Profit Loss ProfitLoss	-40106000	usd
	us-gaap	Profit Loss ProfitLoss	-48734000	usd
CY2023Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3355000	usd
CY2022Q2	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-3576000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-7638000	usd
	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	-6337000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	-14537000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-25525000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-32468000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-42397000	usd
CY2023Q2	PAVM	Preferred Stock Dividends Series B PreferredStockDividendsSeriesB	-75000	usd
CY2022Q2	PAVM	Preferred Stock Dividends Series B PreferredStockDividendsSeriesB	-70000	usd
	PAVM	Preferred Stock Dividends Series B PreferredStockDividendsSeriesB	-149000	usd
	PAVM	Preferred Stock Dividends Series B PreferredStockDividendsSeriesB	-138000	usd
CY2023Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-14612000	usd
CY2022Q2	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-25595000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-32617000	usd
	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-42535000	usd
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104349822	shares
CY2023Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	104349822	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86957352	shares
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	86957352	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100742530	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	100742530	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86689857	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	86689857	shares
CY2023Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	104349822	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86957352	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	100742530	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	86689857	shares
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2023Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.14
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.29
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.49
CY2023Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.14
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.29
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.32
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.49
CY2023Q2	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic NetLossAttributableToCommonStockholdersPerShareBasic	-0.14
CY2023Q2	PAVM	Net Loss Attributable To Common Stockholders Per Share Diluted NetLossAttributableToCommonStockholdersPerShareDiluted	-0.14
CY2022Q2	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic NetLossAttributableToCommonStockholdersPerShareBasic	-0.29
CY2022Q2	PAVM	Net Loss Attributable To Common Stockholders Per Share Diluted NetLossAttributableToCommonStockholdersPerShareDiluted	-0.29
	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic NetLossAttributableToCommonStockholdersPerShareBasic	-0.32
	PAVM	Net Loss Attributable To Common Stockholders Per Share Diluted NetLossAttributableToCommonStockholdersPerShareDiluted	-0.32
	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic NetLossAttributableToCommonStockholdersPerShareBasic	-0.49
	PAVM	Net Loss Attributable To Common Stockholders Per Share Diluted NetLossAttributableToCommonStockholdersPerShareDiluted	-0.49
CY2023Q2	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic NetLossAttributableToCommonStockholdersPerShareBasic	-0.14
CY2022Q2	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic NetLossAttributableToCommonStockholdersPerShareBasic	-0.29
	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic NetLossAttributableToCommonStockholdersPerShareBasic	-0.32
	PAVM	Net Loss Attributable To Common Stockholders Per Share Basic NetLossAttributableToCommonStockholdersPerShareBasic	-0.49
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	31589353	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	25273806	shares

Files In Submission

Name	View Source	Status
pavm-20230630_lab.xml	Edgar Link	unprocessable
pavm-20230630_def.xml	Edgar Link	unprocessable
pavm-20230630_cal.xml	Edgar Link	unprocessable
0001493152-23-028578-index-headers.html	Edgar Link	pending
0001493152-23-028578-index.html	Edgar Link	pending
0001493152-23-028578.txt	Edgar Link	pending
0001493152-23-028578-xbrl.zip	Edgar Link	pending
ex31-1.htm	Edgar Link	pending
ex31-2.htm	Edgar Link	pending
ex32-1.htm	Edgar Link	pending
ex32-2.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
pavm-20230630.xsd	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
pavm-20230630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
form10-q_htm.xml	Edgar Link	completed
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$PAVM
PAVmed Inc. Stock $pavm

2023 Q3 Form 10-Q Financial Statement

#000149315223028578 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PAVM PAVmed Inc. Stock $pavm

2023 Q3 Form 10-Q Financial Statement

#000149315223028578 Filed on August 14, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$PAVM
PAVmed Inc. Stock $pavm